# EDGAR Filing Document

**Accession Number:** 0002081490
**File Stem:** 0001493152-25-026804
**Filing Date:** 2025-12
**Character Count:** 14126
**Document Hash:** 0b180ed66d6d0c080265a408e21efa93
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-25-026804.hdr.sgml**: 20251209

**ACCESSION NUMBER**: 0001493152-25-026804

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20251209

**DATE AS OF CHANGE**: 20251209

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Intercure Ltd.
- **CENTRAL INDEX KEY:** 0001857030
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** L3
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-93664
- **FILM NUMBER:** 251558048

**BUSINESS ADDRESS:**
- **STREET 1:** 85 MEDINAT HA-YEHUDIM STREET
- **CITY:** HERZLIYA
- **STATE:** L3
- **ZIP:** 4676670
- **BUSINESS PHONE:** 972774605012

**MAIL ADDRESS:**
- **STREET 1:** 85 MEDINAT HA-YEHUDIM STREET
- **CITY:** HERZLIYA
- **STATE:** L3
- **ZIP:** 4676670
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Rabinovich Alexander
- **CENTRAL INDEX KEY:** 0002081490

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** C/O, INTERCURE LTD.
- **STREET 2:** 85 MEDINAT HA-YEHUDIM STREET
- **CITY:** HERZLIYA
- **PROVINCE COUNTRY:** L3
- **ZIP:** 4676670

## Ex-4

**Exhibit 4**

**JOINT FILING AGREEMENT**

**PURSUANT TO RULE 13d-1(k)**

The undersigned acknowledge and agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13D shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained herein and therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. The undersigned hereby further agree that this Joint Filing Agreement may be executed in any number of counterparts, each of which when so executed shall be deemed to be an original, but all of which counterparts shall together constitute one and the same instrument.

---

| | | |
|:---|:---|:---|
| Date: December 09, 2025 |  |  |
|  | D.I.M Investments Ltd. | D.I.M Investments Ltd. |
|  | By: | */s/ Alexander Rabinovich* |
|  | Name: | Alexander Rabinovich |
|  | Title: | Director |

---

---

| | |
|:---|:---|
| Date: December 09, 2025 |  |
|  | */s/ Alexander Rabinovich* |
|  | Mr. Alexander Rabinovich |

---

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**InterCure Ltd.**

*(Name of Issuer)*

**Ordinary Shares, no par value**

*(Title of Class of Securities)*

**M549GJ111**

*(CUSIP Number)*

**Alexander Rabinovich**<br>c/o InterCure Ltd.<br>85 Medinat ha-Yehudim Street<br>Herzliya L3 4676670<br>972 77 460 5012

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**03/02/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **M549GJ111** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Alexander Rabinovich** | Name of reporting person<br>**Alexander Rabinovich** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**PF** | Source of funds (See Instructions)<br>**PF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**L3** | Citizenship or place of organization<br>**L3** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**16765453.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**16765453.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**16765453.00** | Aggregate amount beneficially owned by each reporting person<br>**16765453.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**29.4%** | Percent of class represented by amount in Row (11)<br>**29.4%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

| **CUSIP No.** | **M549GJ111** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**D.I.M Investments Ltd.** | Name of reporting person<br>**D.I.M Investments Ltd.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**L3** | Citizenship or place of organization<br>**L3** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**7747805.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**7747805.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**7747805.00** | Aggregate amount beneficially owned by each reporting person<br>**7747805.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**14.2%** | Percent of class represented by amount in Row (11)<br>**14.2%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**CO** | Type of Reporting Person (See Instructions)<br>**CO** | |

---

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Ordinary Shares, no par value

**(b) Name of Issuer:**
InterCure Ltd.

**(c) Address of Issuer's Principal Executive Offices:**
85 Medinat ha-Yehudim Street, Herzliya, L3, 4676670

The aggregate percentage of shares owned by each reporting person named herein is based on 54,512,609 Ordinary Shares outstanding as of April 29, 2025 of the Issuer, as reported in the Issuer's Annual Report on Form 20-F for the year ended December 31, 2024, filed with the Securities and Exchange Commission on May 1, 2025.

**Item 4. Purpose of Transaction**

The information set forth in Item 3 of this Schedule 13D is incorporated by reference in its entirety into this Item 4. The Reporting Persons hold all securities of the Issuer for investment purposes only.

The Ordinary Shares beneficially owned by the Reporting Persons were purchased in a series of investment transactions prior to the Issuer's initial public offering on the Nasdaq Global Market, and through the transactions described herein below, as well as acquisitions in the open market.

Under the securities purchase agreement dated March 2, 2025 among the Issuer and certain investors, or the Private Placement, the Issuer issued to certain investors, including Mr. Rabinovich, (i) an aggregate of 7,349,896 Ordinary Shares, at a purchase price of NIS 4.83 (approximately $1.34) per ordinary share, at a premium above the opening price of the Ordinary Shares on the TASE on December 16, 2024, which was NIS 4.81 per share, or the Determining Date and (ii) warrants, or the Warrants, that have a term of four years, to purchase up to an additional 7,349,896 Ordinary Shares at an exercise price equal to NIS 5.70 (approximately $1.58), at an 18% premium above the opening price of the Ordinary Shares on the Determining Date, which may further increase the proceeds from the Private Placement up to a total of approximately NIS 77 million (approximately $21.5 million) if the Warrants are fully exercised for cash. The consideration for the allocated securities was determined through negotiations between the Company and the investors, based on the opening share price on the Determining Date. The Private Placement was subject to certain closing conditions, which included the approval of the shareholders of the Company, which was later obtained in February 2025.

The Private Placement closed on March 2, 2025. On March 2, 2025, following issuance of 2,070,393 Ordinary Shares and warrants exercisable into 2,070,393 Ordinary Shares in the Private Placement, Mr. Rabinovich became a beneficial owner of approximately 29.3% of the Ordinary Shares, reflecting an increase from the percentage owned as reported in our Annual Report on Form 20-F for the year ended December 31, 2023, which stated that as of April 1, 2024, Mr. Rabinovich beneficially owned 25.73%.

Mr. Rabinovich serves as the Chief Executive Officer, the Chairman and a director of the Issuer and is the Issuer's majority shareholder. Mr. Rabinovich also controls DIM, holds shared voting and dispositive power over the securities held by DIM and may be deemed to be the controlling shareholder over the securities held by DIM. Accordingly, the Reporting Persons may have influence over the corporate activities of the Issuer, including activities that may relate to items described in clauses (a) through (j) of Item 4 of Schedule 13D. Except for the foregoing, the Reporting Persons have no plans or proposals which relate to, or could result in, any of the matters referred to in paragraphs (a) and (c) through (j) of Item 4 of Schedule 13D. The Reporting Persons reserve the right to formulate plans and/or proposals and to take such actions with respect to their investment in the Issuer, including any or all of the actions set forth in clauses (a) through (j) of Item 4 of Schedule 13D.

In his capacity as the Chief Executive Officer the Chairman and a director of the Issuer, from time to time, Mr. Rabinovich may receive share options or other awards of equity-based compensation pursuant to the Issuer's compensation arrangements for officers and directors. In connection with the foregoing, on September 15, 2022, Mr. Rabinovich was granted options to purchase 460,000 Ordinary Shares of the Issuer, which expire four years from the date of issuance with an exercise price of NIS 21.76 per Ordinary Share.

**Item 5. Interest in Securities of the Issuer**

**(a)**
As of the date hereof, Mr. Rabinovich is deemed to beneficially own an aggregate of 16,765,453 Ordinary Shares, representing approximately 29.4% of the outstanding Ordinary Shares. Consists of: (i) 5,240,333 Ordinary Shares, (ii) 460,000 Ordinary Shares issuable upon exercise of options exercisable within 60 days of the date of this Schedule 13D, (iii) 2,070,392 Ordinary Shares issuable upon exercise of warrants exercisable within 60 days of the date of this Schedule 13D, (iv) 7,747,805 Ordinary Shares held by DIM, (v) 1,246,924 Ordinary Shares held by Green Forest Global (A.S.R) Ltd. DIM and Green Forest Global (A.S.R) Ltd. are controlled by Mr. Rabinovich, who holds voting and dispositive power over the securities. The address of DIM is disclosed in Item 2(b) of this Schedule 13D. The address of Green Forest Global (A.S.R) Ltd. is 85 Medinat ha-Yehudim Street, Herzliya, 4676670, Israel.

As of the date hereof, DIM beneficially owns 7,747,805 Ordinary Shares.

**(b)**
The information set forth in Item 5(a) of this Schedule 13D is incorporated by reference in its entirety into this Item 5(b).

**(c)**
Except as described in Item 3 and 4, the Reporting Persons have not effected any transactions in the Ordinary Shares of the Issuer in the 60 days prior to the date of event that requires the filing of this Statement on Schedule 13D. The Reporting Persons have also not effected any transactions in the Ordinary Shares of the Issuer in the past 60 days.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

The information contained in Items 2, 3, 4 and 5 of this Schedule 13D is incorporated by reference herein.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Alexander Rabinovich

**Signature:** /s/ Alexander Rabinovich

**Name/Title:** Alexander Rabinovich

**Date:** 12/09/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** D.I.M Investments Ltd.

**Signature:** /s/ Alexander Rabinovich

**Name/Title:** Alexander Rabinovich, Director

**Date:** 12/09/2025